SC
VRNA

Shay Capital’s Verona Pharma VRNA Stock Holding History

Shay Capital’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,500
Closed -$220K – 417
2023
Q3 		$220K Hold
13,500
– – 0.03% 243
2023
Q2 		$285K Hold
13,500
– – 0.04% 242
2023
Q1 		$271K Buy
+13,500
New +$292K 0.05% 251

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Shay Capital's VRNA Position: Q4 2023 in Review

Shay Capital sold out of Verona Pharma (VRNA) in Q4 2023, closing a stake of 13,500 shares — an estimated $220K sold.

Shay Capital first reported a position in VRNA in Q1 2023 and held it in 3 quarters. The position peaked at $285K in Q2 2023. 117 funds tracked by Wall St. Rank hold VRNA as of Q4 2023.

  • Shay Capital reported no remaining Verona Pharma position as of Q4 2023 after selling out during the quarter.
  • Shay Capital sold 13,500 Verona Pharma shares in Q4 2023, an estimated $220K.
  • Shay Capital first reported a position in Verona Pharma in Q1 2023 and held it in 3 quarters.
  • Shay Capital's Verona Pharma position peaked at $285K in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2023.

Based on Shay Capital's 13F filing for Q4 2023, filed 14 Feb 2024.